Intercellular adhesion molecule 1 and progression of percent emphysema: The MESA Lung Study - 14/02/15

Summary |
Background |
Endothelial intercellular adhesion molecule (ICAM) 1 binds neutrophils and facilitates their transmigration into the lung; E-selectin facilitates leukocyte rolling. As neutrophils contribute to tissue destruction in emphysema and chronic obstructive pulmonary disease, we hypothesized that soluble ICAM-1 (sICAM-1) and E-selectin (sE-selectin) would be associated with longitudinal progression of emphysema and lung function decline.
Methods |
The Multi-Ethnic Study of Atherosclerosis (MESA) enrolled participants 45–84 years old without clinical cardiovascular disease in 2000–02. The MESA Lung Study assessed percent emphysema (<−950 Hounsfield units) on cardiac (2000–07) and full-lung CT scans (2010–12), and spirometry was assessed twice over five years. sICAM-1 and sE-selectin were measured at baseline. Mixed-effect models adjusted for demographics, anthropometry, smoking, C-reactive protein, sphingomyelin and scanner factors.
Results |
Among 1865 MESA Lung participants with measurement of sICAM-1 and percent emphysema the mean log-sICAM-1 was 5.5 ± 0.3 ng/mL and percent emphysema increased 0.73 percentage points (95% CI: 0.34, 1.12; P < 0.001) over ten years. A one SD increase in sICAM-1 was associated with an accelerated increase in percent emphysema of 0.23 percentage points over ten years (95% CI: 0.06, 0.39; P = 0.007). No significant association was found for sE-selectin, or between any adhesion molecule and lung function.
Conclusions |
Higher levels of sICAM-1 were independently associated with progression of percent emphysema in a general population sample.
Le texte complet de cet article est disponible en PDF.Keywords : Emphysema, CT imaging, Endothelium, Intercellular adhesion molecule-1
Plan
Vol 109 - N° 2
P. 255-264 - février 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
